SAN DIEGO, June 18, 2026 — June 18, 2026 — Leads & Copy — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that studies utilizing optical genome mapping (OGM) presented at the 2026 European Society of Human Genetics (ESHG) conference showed a significant increase in participation compared to the previous year, indicating growing global adoption of the technology. A total of 35 studies featured OGM at ESHG 2026, representing a 67% rise from the 21 studies presented in 2025.
The research spanned 17 countries, an increase from 12 in 2025, and covered five global regions: Europe, North America, South America, Asia, and the Middle East. Rare and constitutional genetic disorders were the predominant research theme, accounting for approximately half of the presented studies. Other significant application areas included hematologic malignancies, solid tumors, hereditary cancer, reproductive health, and cardiovascular genomics. Europe was the leading continent for study contributions, with Brazil identified as the top-contributing country.
The studies incorporated OGM both independently and in conjunction with other methods such as chromosomal microarray, classical karyotyping, and long- and short-read sequencing. This year-over-year expansion in scientific content and geographic reach underscores the increasing interest in comprehensive structural variant detection within clinical research and highlights the potential benefits of integrating OGM with sequencing technologies.
“I am extremely impressed with the ongoing growth in studies featuring optical genome mapping as the leading platform that we expect to be instrumental in ushering in the next generation of cytogenomics and helping to drive a digital pathology revolution together with sequencing,” said Alka Chaubey, Ph.D., FACMG, chief medical officer of Bionano. “Presentations at ESHG 2026 demonstrated the ability of OGM to resolve complex genomic rearrangements, identify cryptic structural variants, and provide insights that may not be accessible through traditional cytogenetic and sequencing approaches, which is something the cytogenetics and molecular pathology communities have been seeking for decades.”
Presentations at ESHG 2026 included a range of platform presentations and posters detailing the application of OGM across various genetic research areas. Topics covered recurrent inversions, rare coding and structural variants in psychiatric disorders, CTCF-boundary deletions, and the identification and interpretation of structural variants. Further studies explored genomic differences in multiple myeloma, the evaluation of OGM for rapid methylation and copy number profiling in gliomas, and copy number alterations in pediatric diffuse midline gliomas.
Additional research highlighted complex familial chromosome rearrangements associated with intellectual disability and congenital heart defects, genome-wide association studies identifying common variants in arrhythmogenic cardiomyopathy, and comparative studies of OGM versus long-read sequencing. The utility of OGM in detecting cryptic structural aberrations in acute myeloid leukemia, constitutional chromoanagenesis, and its role in prospective evaluations alongside long-read genome sequencing were also presented. Furthermore, studies showcased the implementation of OGM in clinical genetics, the analysis of isolated humeroradial synostosis, and the detection of relevant cryptic alterations in myelodysplastic neoplasms.
The scientific program for the event is available on the ESHG website.
About Bionano Genomics
Bionano is a provider of genome analysis solutions designed to help researchers and clinicians address complex biological and medical questions. The company’s mission is to transform genomic understanding through its optical genome mapping (OGM) solutions, diagnostic services, and software. Bionano offers OGM solutions for diverse applications in basic, translational, and clinical research. Additionally, the company provides an industry-leading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions utilizing its proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the company also provides OGM-based diagnostic testing services. Bionano’s products are intended for research use only and not for diagnostic procedures.
Source: Bionano Genomics, Inc.